How 'hidden mutations' contribute to HIV drug resistance

Jul 31, 2008

One of the major reasons that treatment for HIV/AIDS often doesn't work as well as it should is resistance to the drugs involved. Now, scientists at McGill University have revealed how mutations hidden in previously ignored parts of the HIV genome play an important role in the development of drug resistance in AIDS patients. Their study will be published Aug. 8 in the Journal of Biological Chemistry.

"HIV develops resistance very rapidly, and once that happens, drugs don't work as well as they theoretically should, or they stop working altogether," explained Dr. Matthias Götte, an associate professor in McGill's Department of Microbiology and Immunology. "Physicians routinely have the patient's virus tested for resistance in advance of treatment to help make the appropriate clinical decisions."

The study was conducted by a team of researchers led by Dr. Götte at McGill's Faculty of Medicine, with assistance from the B.C. Centre for Excellence in HIV/AIDS at the University of British Columbia (UBC). It was funded by the Canadian Institutes for Health Research (CIHR).

HIV genotype testing is now widely established in HIV drug resistance screening. However, for technical and economic reasons, the entire HIV genome is usually not sequenced.

"The focus has been on specific areas of the HIV genome where we expect these resistance-conferring mutations to occur," Dr. Götte said. "We focus on a particular sequence on an important gene from amino acid 1 to 300, and as such, we miss roughly a third of this gene. Until recently, most researchers believed that this hidden area was of little clinical significance."

Within the last few years, however, studies started to suggest that the first 300 amino acids alone may not completely describe the drug resistance landscape. Dr. Götte and his colleagues selected a few of these previously uncharacterized mutations and subjected them to a battery of highly sensitive biochemical tests.

"People were skeptical," Dr. Götte said. "The mechanism about how these mutations could be involved in resistance was not clear. However, in our paper, we present data that explains in considerable detail how these mutations work."

Nevertheless, he cautioned, the debate about whether to routinely screen these areas of the HIV genome will still likely continue for some time.

"It's extremely time-consuming and expensive to validate genotype testing," he said. "However, we probably will be testing these areas in a couple of years."

Source: McGill University

Explore further: Cuba becomes first nation to eliminate mother-to-child HIV

Related Stories

Mutation breaks HIV's resistance to drugs

Sep 13, 2012

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers, including MU scientists, found that one of those mutations, called ...

Researchers trace HIV mutations that lead to drug resistance

Jan 11, 2010

Chemists at UC San Diego and statisticians at Harvard University have developed a novel way to trace mutations in HIV that lead to drug resistance. Their findings, once expanded to the full range of drugs available to treat ...

Recommended for you

CDC examines prevalence of undiagnosed HIV

21 hours ago

(HealthDay)—Many people have undiagnosed HIV, with the prevalence varying by geographic area, according to a report published in the June 26 issue of the U.S. Centers for Disease Control and Prevention's ...

Potential new HIV therapy seen in immune cells

Jun 29, 2015

A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The ...

More secondary schooling reduces HIV risk

Jun 29, 2015

Longer secondary schooling substantially reduces the risk of HIV infection—especially for girls—and could be a very cost-effective way to halt the spread of the virus, according to researchers from Harvard ...

Bill Gates hopeful of AIDS vaccine in 10 years

Jun 26, 2015

Billionaire and philanthropist Bill Gates, who spends millions of dollars on AIDS drug development, said Friday he hoped for a vaccine against the disease within the next decade as a cure remains far off.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.